Audited annual filings, TTM ratios and consensus forward estimates
Wall Street price targets and rating actions
Revenue disaggregation per 10-K filing
Annual filings (FY) with consensus forward estimates (hatched)
Free float vs. closely held shares
13F institutional holdings are not available in the current data plan.
SEC Form 4 filings
| Date | Insider | Role | Type | Shares @ price | Value |
|---|---|---|---|---|---|
| Oct 13, 26 | Murphy Andrew J | officer: Co-Chief Scientific Officer | M-Exempt | 17,000 @ $381.92 | $6.49M |
| Oct 13, 26 |
| Murphy Andrew J |
| officer: Co-Chief Scientific Officer |
| F-InKind |
| 12,853 @ $754.58 |
| $9.70M |
| Oct 14, 26 | Murphy Andrew J | officer: Co-Chief Scientific Officer | S-Sale | 6 @ $753.76 | $4.52K |
| Oct 14, 26 | Murphy Andrew J | officer: Co-Chief Scientific Officer | S-Sale | 35 @ $755.91 | $26.46K |
| Oct 14, 26 | Murphy Andrew J | officer: Co-Chief Scientific Officer | S-Sale | 16 @ $757.68 | $12.12K |
| Oct 14, 26 | Murphy Andrew J | officer: Co-Chief Scientific Officer | S-Sale | 24 @ $758.16 | $18.20K |
| Oct 14, 26 | Murphy Andrew J | officer: Co-Chief Scientific Officer | S-Sale | 14 @ $759.96 | $10.64K |
| Oct 14, 26 | Murphy Andrew J | officer: Co-Chief Scientific Officer | S-Sale | 74 @ $760.65 | $56.29K |
FY2025 · 10-K disclosure
FY2025 · 10-K disclosure
SEC EDGAR filings · last 12 months
| Form | Filed | Accepted | Document |
|---|---|---|---|
| 4 | Oct 15, 2026 | 2026-10-15 16:02:50 | View |
| 8-K | Oct 6, 2026 | 2026-10-06 07:51:50 | View |
| 8-K | Sep 30, 2026 | 2026-09-30 16:14:08 | View |
| 4 | Sep 3, 2026 | 2026-09-03 16:50:59 | View |
| 4 | Sep 3, 2026 | 2026-09-03 16:47:22 | View |
| 4 | Aug 21, 2026 | 2026-08-21 16:01:23 | View |
| N-PX | Aug 20, 2026 | 2026-08-20 16:11:46 | View |
| 4 | Aug 20, 2026 | 2026-08-20 16:01:28 | View |
| 4 | Aug 12, 2026 | 2026-08-12 16:16:51 | View |
| 4 | Aug 12, 2026 | 2026-08-12 16:14:48 | View |
Proxy statement (DEF 14A) disclosures
TTM vs. 5-year historical average (annual ratios)
| Metric | REGN | Historical (5Y) / ref | Status |
|---|---|---|---|
| P/E ratio (TTM) | 18.7x | 17.0x · sector 20.7x | In line |
| Forward P/E (FY26E) | 13.4x | EPS est. 58.55 | Discount |
| Price / Book | 2.5x | 3.2x | Discount |
| Price / Sales | 5.2x | 5.7x | In line |
| EV / EBITDA | 13.9x | 14.0x | In line |
| Return on equity | 13.8% | — | Healthy |
| Gross margin | 84.9% | 84.7% | In line |
| Debt / Equity | 0.06 | 0.11 | Conservative |
| Piotroski / Altman Z | 7/9 | Z 7.29 | Safe zone |
Discounted cash flow model
1255 daily bars · split adjusted
Daily · Wilder smoothing
Classic floor pivots from 2026-10-19
Computed from daily OHLCV bars
| Indicator | Value | Type | Action |
|---|---|---|---|
| RSI (14) | 53.95 | Oscillator | Neutral |
| Stochastic %K (14, 3, 3) | 77.38 | Oscillator | Neutral |
| Williams %R (14) | -31.38 | Oscillator | Neutral |
| MACD (12, 26, 9) | -0.94 (Hist 5.73) | Oscillator | Buy |
| Average Directional Index (14) | 18.41 (+DI 28.4 / -DI 19.3) | Trend | Neutral |
Stock news · updated daily
Regeneron (REGN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
At the end of October, Regeneron Pharmaceuticals, Inc. will report its results for Q3. As a reminder, REGN's Q2 revenue rose 18.8% quarter-on-quarter and 16.6% YoY to $4.29 billion, primarily due to the strong performance of Dupixent. On October 12, Regeneron reported positive Phase 3 OPTIMA results, demonstrating sustained Pasatru efficacy in reducing new HO lesions and disease flare-ups in people with FOP.
Current price $782.04
Latest analyst grade actions
| Date | Firm | Action | Previous | New grade |
|---|---|---|---|---|
| Oct 15, 26 |
| EMA 20 | 769.56 | MA | Buy |
| SMA 20 | 763.88 | MA | Buy |
| EMA 50 | 766.56 | MA | Buy |
| SMA 50 | 790.81 | MA | Sell |
| SMA 200 | 735.47 | MA | Strong Buy |
Reported EPS vs. consensus estimate
| Report date | EPS est. | EPS actual | Surprise | Revenue |
|---|---|---|---|---|
| Jul 30, 2026 | 10.16 | 14.29 | Beat 40.6% | $4.29B |
| Apr 29, 2026 | 8.91 | 9.47 | Beat 6.3% | $3.61B |
| Jan 30, 2026 | 10.74 | 11.44 | Beat 6.5% | $3.88B |
| Oct 28, 2025 | 9.65 | 11.83 | Beat 22.6% | $3.75B |
| Aug 1, 2025 | 8.43 | 12.89 | Beat 52.9% | $3.68B |
| Apr 29, 2025 | 8.62 | 8.22 | Miss -4.6% | $3.03B |
| UBS |
| upgrade |
| Neutral |
| Buy |
| Oct 8, 26 | RBC Capital | maintain | Sector Perform | Sector Perform |
| Oct 7, 26 | Morgan Stanley | maintain | Equal Weight | Equal Weight |
| Oct 7, 26 | Truist Securities | maintain | Buy | Buy |
| Oct 6, 26 | JP Morgan | maintain | Overweight | Overweight |
| Oct 1, 26 | Jefferies | maintain | Buy | Buy |
| Oct 1, 26 | Argus Research | upgrade | Hold | Buy |
| Sep 29, 26 | RBC Capital | maintain | Sector Perform | Sector Perform |
| Sep 10, 26 | HSBC | maintain | Buy | Buy |